Based on the preclinical finding, CB-839, combined with radiation and temozolomide, is being utilized in phase 1 clinical trial of IDH-mutant astrocytoma (Table 2; ClinicalTrials.gov NCT03528642). The gene discussed is IDH1; the disease is astrocytoma (excluding glioblastoma).